PRKAG2 syndrome is an autosomal dominant Atrium Therapeutics has received clearance from the US Food and Drug Administration ...
Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the U.S. Food and Drug Administration ...
US FDA clears Atrium Therapeutics’ IND application for ATR 1072 to treat of PRKAG2 syndrome: San Diego Wednesday, July 15, 2026, 13:00 Hrs [IST] Atrium Therapeutics, Inc., a bio ...
The second universal definition of heart failure moves away from specific EF cutoffs to classify patients into clinically actionable groups.
This article is authored by Venkataswamy Eswarachari, associate vice president and senior director, Lab Operations, MedGenome.
As the aorta gains recognition as a functioning organ rather than a simple blood conduit, the lack of standardised imaging ...
ATR 1072, a small interfering RNA drug, is Atrium's first precision cardiology program to enter the clinic since its launch earlier this year.
Masonic Medical Research Institute will host its first telethon Tuesday, Oct. 6, 2026, streaming live across the institute's ...
Latest news and breakthroughs on Palpitations And Arrhythmias. Section has 2894 news items. Avail 'Palpitations And Arrhythmias News Widget' free from Medindia - Page 193 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results